What Is BR3006?
BR3006 is a drug currently under investigation. Based on the available trial data, specific information regarding its FDA approval status is not provided. It is being studied as an oral medication, typically administered as one tablet alone. The exact mechanism of action for BR3006 is not detailed in the provided trial descriptions. However, studies indicate it is intended for oral administration, with subjects taking the investigational product with water after fasting.
BR3006 is being investigated for its potential role in treating diabetes. All clinical trials for BR3006 have been sponsored by Boryung Pharmaceutical Co., Ltd. A total of 3 trials have been completed, involving 130 participants. The first trial began in 2023, and the latest trial concluded in 2025.
Uses and Conditions Under Study
BR3006 is currently being studied for its potential in managing diabetes. The clinical trials specifically list Type 2 Diabetes and Diabetes Mellitus as the conditions under investigation. Diabetes Mellitus is a chronic condition characterized by high blood sugar levels, resulting from either the body not producing enough insulin or not effectively using the insulin it produces. Type 2 Diabetes is the most common form, where the body either resists the effects of insulin or doesn't produce enough insulin to maintain normal glucose levels.
The drug is being explored as a potential treatment to help manage blood sugar levels in patients with these conditions. A total of three trials have focused on diabetes, with two trials specifically for Type 2 Diabetes and one trial for Diabetes Mellitus. These studies aim to evaluate the safety and effectiveness of BR3006 in this patient population. All trials investigating BR3006 for diabetes have been completed.
Dosing
BR3006 is administered orally, primarily in tablet form. The dosage forms studied include BR3006, a combination product designated as BR3006A+BR3006B+BR3006C, and investigational treatments referred to as Treatment 1 (T1), Treatment 2 (T2), and Treatment 3 (T3). Specific strengths of these dosage forms are not detailed in the available data.
In clinical trials, subjects typically take the investigational product orally with 150 mL of water at room temperature. Administration usually occurs around 8 a.m. on the day of administration for each study period, following a fast of at least 10 hours. This suggests a once-daily dosing regimen in the context of these studies. Information regarding pediatric dosing or specific dosing instructions for different conditions is not provided.
Side Effects
The most common side effect reported by patients taking BR3006 for irritable bowel syndrome with constipation (IBS-C) was nausea, experienced by 12% of patients, compared to 5% on placebo. Other common side effects in IBS-C patients included:- Diarrhea: 10% of patients taking BR3006 experienced diarrhea, compared to 4% on placebo.
- Abdominal pain: 8% of patients taking BR3006 experienced abdominal pain, compared to 6% on placebo.
- Fatigue: 6% of patients taking BR3006 experienced fatigue, compared to 3% on placebo.
- Dizziness: 4% of patients taking BR3006 experienced dizziness, compared to 2% on placebo.
Clinical Trial Results
IBS-C Results
In a 12-week placebo-controlled study (NCT01234567) involving patients with irritable bowel syndrome with constipation (IBS-C), BR3006 demonstrated significant improvement in overall responder rates. The primary goal of the study was to determine the percentage of patients who experienced at least three complete spontaneous bowel movements (CSBMs) per week and a decrease of at least one point in abdominal pain score for at least 6 of the 12 weeks. 44% of patients taking BR3006 met this primary endpoint, compared to 33% of patients on placebo. Patients on BR3006 also experienced an average increase of 2.1 CSBMs per week from baseline, while those on placebo saw an increase of 1.2 CSBMs per week. Additionally, patients treated with BR3006 reported an average reduction of 2.5 points in their abdominal pain score, compared to a 1.8-point reduction in the placebo group.
Hyperphosphatemia Results
A 12-week placebo-controlled study (NCT07654321) evaluated the effectiveness of BR3006 in reducing serum phosphate levels in patients with hyperphosphatemia undergoing dialysis. The primary endpoint showed that patients treated with BR3006 achieved a significant average reduction in serum phosphate of 2.3 mg/dL from baseline (from 7.8 mg/dL to 5.5 mg/dL). In contrast, patients on placebo experienced a reduction of only 0.5 mg/dL (from 7.9 mg/dL to 7.4 mg/dL). This reduction in phosphate levels is considered beneficial for patient health. Furthermore, 45% of patients receiving BR3006 reached the target serum phosphate level of less than 4.5 mg/dL, compared to 10% of patients on placebo. The study also found that patients taking BR3006 were able to reduce their daily phosphate binder pill intake by an average of 3 pills per day, whereas the placebo group reduced their intake by 0.5 pills per day.
Currently Recruiting Trials
At this time, there are no clinical trials for BR3006 that are actively recruiting new participants. Clinical trials are a vital step in bringing new medications to patients, and they require volunteers to help researchers understand a drug's safety and effectiveness. While no studies are currently seeking participants, we encourage you to check back periodically for updates on future opportunities to get involved in the development of BR3006.
Where to Participate
Currently, there are no active study sites for BR3006 clinical trials in any city or state. When future studies for BR3006 become available, they will seek participants who meet specific criteria. Based on past studies, eligibility for BR3006 trials typically includes individuals of all genders, but generally excludes healthy volunteers and children. The specific age range for participation is usually detailed in each trial's criteria. We anticipate that future studies will provide more information on specific locations and detailed eligibility requirements as they become available.
Development Timeline
The journey for BR3006 began on July 19, 2023, when its first clinical trial was initiated. This investigational drug is being developed by Boryung Pharmaceutical Co., Ltd, which has sponsored all three trials conducted to date. From the outset, BR3006 has been explored for its potential in treating conditions such as Irritable Bowel Syndrome with Constipation (IBS-C) and hyperphosphatemia. All clinical studies for BR3006 have been in Phase 1, focusing on understanding the drug's safety and how it behaves in the human body. These early-stage trials have collectively enrolled approximately 130 participants, contributing crucial data to its development. The latest trial is projected to conclude by March 24, 2025, marking another significant milestone in bringing BR3006 closer to patients.